NEW YORK (GenomeWeb) — Goldman Sachs on Tuesday released an omnibus report of its views on specific companies and sectors of the life sciences industry. The investment bank upgraded shares of Agilent to Buy; Thermo Fisher Scientific to the Americas Conviction Buy List; and Myriad to Neutral. Goldman also downgraded PerkinElmer to Sell and Danaher and Laboratory Corporation of America to Neutral.

The bank also raised its view of the life science tools sector to Attractive, lowered its view of the labs sector to Neutral, and reiterated its Neutral view of the diagnostics market.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.